Deepak Anand Outlines International Cannabis Export Path Post-Reform

Schedule III Reclassification Activates Export Authority

Federal rescheduling from Schedule I to Schedule III removes the blanket export prohibition that applied to cannabis under 21 U.S.C. § 953(a). Schedule I substances face an absolute export bar absent specific DEA waiver. Schedule III substances may be exported under the registration and quota framework in 21 CFR Part 1312, which governs export declarations, foreign import permits, and shipment documentation.

Anand noted that the DEA's existing export registration process for Schedule III controlled substances—used for ketamine, anabolic steroids, and certain stimulants—provides the administrative template. Exporters must hold a valid DEA registration, file DEA Form 161 (export declaration) for each shipment, and obtain a corresponding import permit from the destination country's competent authority.

Single Convention Treaty Obligations Remain Binding

The United States remains a signatory to the 1961 Single Convention on Narcotic Drugs, which classifies cannabis in Schedule I and Schedule IV of that treaty. Rescheduling under the Controlled Substances Act doesn't alter U.S. obligations under international law. Exporting cannabis to another Single Convention signatory requires that the destination country issue an import certificate pursuant to Article 31 of the Convention, which mandates government-to-government authorization for cross-border narcotic transfers.

Anand emphasized that this dual-layer compliance—domestic CSA registration plus treaty-compliant import certification—creates a narrow but viable export pathway. Countries that have established regulated cannabis markets and issued import licenses (Canada, Germany, Israel) represent the primary near-term destinations.

DEA Registration and Quota Allocation for Exporters

Exporters must secure a DEA Schedule III bulk manufacturer or distributor registration and operate within annual production quotas set by the DEA's Diversion Control Division. The quota system, codified in 21 CFR § 1303.11, limits the aggregate quantity of Schedule III substances manufactured or imported each calendar year. Cannabis cultivators and processors seeking export authority must apply for quota allocation in the fourth quarter of the preceding year.

Specific quota figures for cannabis under Schedule III? The DEA hasn't published them yet. Historical precedent from other Schedule III substances suggests initial quotas will be conservative, expanding as the agency gains operational data on diversion risk and international demand.

State-Level Export Licensing Adds Compliance Layer

State cannabis regulators retain authority over intrastate cultivation, processing, and distribution. Several states—including California, Oregon, and Michigan—have begun drafting export-specific licensing categories in anticipation of federal reform. A cannabis business must hold both a valid state export license and a federal DEA registration to lawfully export product. States without explicit export licensing frameworks may require legislative or regulatory amendments before operators can pursue cross-border trade.

280E Relief Doesn't Extend to Export Operations

Rescheduling to Schedule III removes the IRC § 280E deduction disallowance for domestic cannabis businesses, but export operations face distinct tax treatment under Subpart F and FDII provisions. Foreign-derived intangible income (FDII) rules in IRC § 250 allow a partial deduction for income from goods sold for foreign use. Cannabis exporters must work through transfer-pricing rules, foreign tax credit limitations, and potential controlled foreign corporation (CFC) implications if they establish offshore distribution entities.

Anand noted that exporters should model effective tax rates under FDII versus direct export scenarios, as the deduction phases in over multiple tax years and depends on the ratio of foreign to total income.

Banking and Payment Rails Remain Constrained

Schedule III rescheduling doesn't remove cannabis from the Bank Secrecy Act's Marijuana-Related Business (MRB) guidance issued by FinCEN in 2014. That guidance remains in effect until FinCEN issues a superseding rule or Congress enacts the SAFE Banking Act. International wire transfers for cannabis exports will continue to trigger enhanced due diligence and suspicious activity report (SAR) filings under current FinCEN policy.

Exporters may face correspondent banking challenges. Foreign financial institutions often decline to process U.S. cannabis transactions due to reputational risk and anti-money laundering (AML) compliance concerns. Anand recommended establishing dedicated export-only bank accounts and maintaining granular transaction documentation to satisfy both U.S. and foreign AML requirements.

What Operators Should Watch

DEA rulemaking on cannabis-specific export procedures is expected in Q4 2026. The agency must clarify whether existing Schedule III export forms and timelines apply without modification or whether cannabis will be subject to additional reporting requirements. For full background on this story, see the CannIntel topic hub on cannabis international export.

Operators should monitor bilateral negotiations between the U.S. and key destination countries. Germany's import licensing framework and Canada's existing Cannabis Act provisions offer the clearest near-term pathways. Israel's medical cannabis export program may open reciprocal import channels once U.S. domestic rescheduling is finalized.